Recent Progress on Tumor Microenvironment‐Activated NIR‐II Phototheranostic Agents with Simultaneous Activation for Diagnosis and Treatment

Abstract Malignant tumors seriously threaten human life and well‐being. Emerging Near‐infrared II (NIR‐II, 1000–1700 nm) phototheranostic nanotechnology integrates diagnostic and treatment modalities, offering merits including improved tissue penetration and enhanced spatiotemporal resolution. This remarkable progress has opened promising avenues for advancing tumor theranostic research. The tumor microenvironment (TME) differs from normal tissues, exhibiting distinct attributes such as hypoxia, acidosis, overexpressed hydrogen peroxide, excess glutathione, and other factors. Capitalizing on these attributes, researchers have developed TME‐activatable NIR‐II phototheranostic agents with diagnostic and therapeutic attributes concurrently. Therefore, developing TME‐activatable NIR‐II phototheranostic agents with diagnostic and therapeutic activation holds significant research importance. Currently, research on TME‐activatable NIR‐II phototheranostic agents is still in its preliminary stages. This review examines the recent advances in developing dual‐functional NIR‐II activatable phototheranostic agents over the past years. It systematically presents NIR‐II phototheranostic agents activated by various TME factors such as acidity (pH), hydrogen peroxide (H 2 O 2 ), glutathione (GSH), hydrogen sulfide (H 2 S), enzymes, and their hybrid. This encompasses NIR‐II fluorescence and photoacoustic imaging diagnostics, along with therapeutic modalities, including photothermal, photodynamic, chemodynamic, and gas therapies triggered by these TME factors. Lastly, the difficulties and opportunities confronting NIR‐II activatable phototheranostic agents in the simultaneous diagnosis and treatment field are highlighted.